Comparative prospective, double‐blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of bone
Authors:
- 1 June 1995
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 38 (6) , 851-858
Abstract
Objective. To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of active Paget's disease of bone.Methods. We studied 234 patients with radiologic lesions characteristic of Paget's disease of bone and serum alkaline phosphatase (AP) concentrations at least twice the upper limit of normal, in a prospective, randomized, double‐blind, multicenter clinical trial lasting 6 months. Patients were randomly allocated into 1 of 3 treatment groups: tiludronate for 3 months followed by placebo for 3 months, tiludronate for 6 months, or etidronate for 6 months. Serum AP levels and urinary hydroxyproline excretion were measured at baseline and after 3 months and 6 months. Patients with a reduction of at least 50% in the serum AP concentration were considered to be responders.Results. After 3 months, the proportion of responders was higher in the tiludronate group (57.4%) than in the etidronate group (13.9%) (P < 0.0001). In the etidronate group, this percentage was lower among patients who had received previous treatment with a bisphosphonate (2.3%) than among those who had not (28.6%) (P < 0.01). Previous bisphosphonate treatment was not associated with response in the tiludronate group. After 6 months, the proportion of responders did not differ between the 2 tiludronate groups (60.3% and 70.1%), but was lower in the etidronate group (25.3%) (P < 0.0001). There was a higher proportion of patients with treatment‐resistant disease ( < 25% reduction of serum AP) in the etidronate group (51.9%) than in the tiludronate 3‐month group (17.9%) or the tiludronate 6‐month group (19.5%) (P < 0.0001). Gastrointestinal disturbances were more common, and occurred earlier, with tiludronate, but they were mostly mild, requiring no treatment.Conclusion. Tiludronate at 400 mg/day for 3 months or 6 months is more effective than the same dosage of etidronate for 6 months in the treatment of Paget's disease.Keywords
This publication has 25 references indexed in Scilit:
- Evaluation of the efficacy and safety of oral tiludronate in paget's disease of boneArthritis & Rheumatism, 1992
- Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonateClinical Rheumatology, 1989
- Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl)thiomethylene bisphosphonate, in the treatment of Paget's disease of boneBone, 1988
- ETIDRONATE AND THE RISK OF FRACTURESThe Lancet, 1985
- Diphosphonates: History and mechanisms of actionMetabolic Bone Disease and Related Research, 1981
- Long‐term therapy of paget's disease of bone with ehdpArthritis & Rheumatism, 1980
- Use of etidronate (ehdp) in paget's disease of boneArthritis & Rheumatism, 1980
- Bone histomorphometry in pacet's disease quantitative and dynamic analysis of pagetic and nonpagetic bone tissueArthritis & Rheumatism, 1980
- Paget's Disease of Bone—Clinical Evaluation and Treatment with DiphosphonateAustralian and New Zealand Journal of Medicine, 1979
- DIAGNOSTIC PROCEDURES IN DISORDERS OF CALCIUM METABOLISMClinical Endocrinology, 1978